GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » scPharmaceuticals Inc (NAS:SCPH) » Definitions » 1-Year ROIIC %

SCPH (scPharmaceuticals) 1-Year ROIIC % : -99.18% (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is scPharmaceuticals 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. scPharmaceuticals's 1-Year ROIIC % for the quarter that ended in Sep. 2024 was -99.18%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for scPharmaceuticals's 1-Year ROIIC % or its related term are showing as below:

SCPH's 1-Year ROIIC % is ranked worse than
67.8% of 1416 companies
in the Biotechnology industry
Industry Median: -11.175 vs SCPH: -99.18

scPharmaceuticals 1-Year ROIIC % Historical Data

The historical data trend for scPharmaceuticals's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

scPharmaceuticals 1-Year ROIIC % Chart

scPharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only 124.84 107.06 66.80 129.66 -338.16

scPharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 274.27 -338.16 -384.44 -154.39 -99.18

Competitive Comparison of scPharmaceuticals's 1-Year ROIIC %

For the Biotechnology subindustry, scPharmaceuticals's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


scPharmaceuticals's 1-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, scPharmaceuticals's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where scPharmaceuticals's 1-Year ROIIC % falls into.



scPharmaceuticals 1-Year ROIIC % Calculation

scPharmaceuticals's 1-Year ROIIC % for the quarter that ended in Sep. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -63.69 (Sep. 2024) - -49.641 (Sep. 2023) )/( 22.605 (Sep. 2024) - 8.44 (Sep. 2023) )
=-14.049/14.165
=-99.18%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


scPharmaceuticals  (NAS:SCPH) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


scPharmaceuticals 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of scPharmaceuticals's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


scPharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
25 Mall Road, Suite 203, Burlington, MA, USA, 01803
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.
Executives
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
5am Partners Iv, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Jack A. Khattar director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
John H Tucker director, officer: President and CEO INDEVUS PHARMACEUTICALS, INC., 99 HAYDEN AVENUE, LEXINGTON MA 02421
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
William Tober Abraham director C/O SCPHARMACEUTICALS INC., 2400 DISTRICT AVENUE, SUITE 310, BURLINGTON MA 01803
Sara Bonstein director 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Andrew J. Schwab 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc other: See Remarks 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p. other: See Remarks 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
Orbimed Genesis Gp Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rachael Nokes officer: See Remarks C/O SCPHARMACEUITCALS, INC., 2400 DISTRICT AVENUE, BURLINGTON MA 01803